All animal experiments were conducted in strict compliance with the guidelines for laboratory animal care and utilization established by the National Institutes of Health. Wild-type (WT) and HCAR2 knockout (KO) C57BL/6 mice (6–8 weeks old, strain NO. T006705) were purchased from Gempharmatech (Nanjing, Jiangsu, China) and housed under standard laboratory conditions. They were given ad libitum access to water and food and maintained on a 12-h light/12-h dark cycle. Mice were intraperitoneally administered with a daily dose of corticosterone (Cor, 20 mg/kg, 50-22-6, Aladdin, Shanghai, China) for a continuous three-week period to establish a rodent model of depression. To evaluate the therapeutic effects of HCAR2 activation in this model, mice were then randomly assigned to one of four groups for a two-week treatment period: a control group (administered saline), a Cor group, an HCAR2 agonist (MK-6892, HY-10680, MedChemExpress, Monmouth Junction, NJ, USA) group, and a combined Cor+MK-6892 group (Fig. 1A). To investigate whether the antidepressant and neuroprotective effects of HCAR2 activation were mediated through its action on microglia, mice were administered PLX5622 chow (PLX, HY-114153, Monmouth Junction, NJ, USA) throughout the experimental period to deplete microglia in vivo. AIN-76A chow (Shanghai Yubo Bio-technology Co., Ltd.02960097-CF, Shanghai, China) served as the vehicle (Veh) control in this study. Mice were randomly assigned to one of three groups: Cor+MK-6892, Cor+Veh+MK-6892, or Cor+PLX+MK-6892 (Fig. 1B). Behavioral tests were conducted within one week following the completion of drug treatment. The mice were then anesthetized with a mixture of xylazine (7361-61-7; Merck, Rahway, NJ, USA; 10 mg/kg, i.p.) and ketamine (H20023609; Jiuxu Pharmaceutical Co., Ltd., Jinhua, Zhejiang, China; 90 mg/kg, i.p.), after which samples were collected for subsequent analyses. In particular, a volume of 2 µL of MK-6892 (100 mg/kg) or saline was administered via intracerebroventricular infusion. Mice were euthanized using gradual CO₂ inhalation. CO₂ was introduced into a transparent chamber at a flow rate displacing 20% of the chamber volume per minute until the final CO₂ concentration exceeded 70%. After confirming respiratory arrest, this concentration was maintained for an additional 5 minutes to ensure death.

Fig. 1.

Experimental timeline utilized in this study. (A) Timeline for assessing the therapeutic effects of HCAR2 activation in a murine model of depression. (B) Timeline for assessing the therapeutic effects of HCAR2 activation following microglia depletion in a murine model of depression. HCAR2, hydroxy-carboxylic acid receptor 2.

The mice underwent a battery of behavioral tests designed specifically to evaluate depression-like behaviors. For the tail suspension test, the tail was gently secured to the tail hanger, ensuring the animal’s head was positioned downward, with a distance of approximately 30 cm maintained from the bottom of the hanger. Following the adaptation period, the duration of immobility was measured during a 4-minute interval. For the forced swimming test, the water temperature in the test chamber was adjusted to a range of 23–25 °C prior to commencing the experiment. Mice were acclimatized to swimming one day before the experiment. At 24 h after the acclimatization period, the length of time of immobility was recorded over a period of 5-minute duration. For the sucrose preference test, mice were first acclimatized to sucrose water over a 24-h adaptation period. Specifically, each rat was provided with two bottles: one containing 1% sucrose solution (wt/vol) and the other containing purified water. The bottles were randomly positioned on either the right or left side of each cage. To control for position bias, the position of each bottle was switched after 12 h. The sucrose preference test was conducted after this adaptation period. Following baseline measurements, the mice underwent a 24-h period of food and water deprivation. Thereafter, they were promptly subjected to a 12-h sugar preference test. For the open field test, mice were placed in a square arena measuring 1 $\times$ 1 meter. After a period of acclimatization, the frequency of rearing behavior was recorded during a 4-minute observation period.

The sample was fixed in a solution of 95% ethanol and ice-cold acetone for 20 minutes, and subsequently rinsed twice with phosphate-buffered saline (PBS) to remove residual fixative. The samples were then stained with hematoxylin solution for 2–3 minutes to visualize the nuclei, followed by thorough rinsing with deionized water to ensure complete removal of excess stain. Next, the samples were immersed in eosin solution for 1 minute to stain the cytoplasm, followed by rinsing with deionized water. After air drying, the coverslips were mounted using neutral mounting medium. Observations and photographic documentation were performed 24 h later using an inverted laser confocal microscope (FV1200MPE-share, Olympus, Tokyo, Japan).

Fresh tissues were fixed in 10% neutral buffered formalin for 48 h, followed by routine dehydration and embedding procedures. The tissues were sectioned into 6–8 µm thick slices, dewaxed, and rinsed multiple times with distilled water. Sections were then immersed in toluidine blue solution and incubated in a thermostat (FP89-HL, Julabo, Seelbach, Germany) maintained at 50–60 °C for 25–50 minutes to ensure optimal staining. After rinsing with distilled water, sections underwent a stepwise dehydration process using ethanol. Xylene was subsequently used for clarification, and the specimens mounted using a neutral mounting medium.

ELISA was used to quantify the serum concentrations of 5-hydroxytryptamine (5-HT, EEL006, Invitrogen, Carlsbad, CA, USA) and noradrenaline (NA, EEL010, Invitrogen, Carlsbad, CA, USA) as recommended by the manufacturer of the commercially available kits. ELISA was also used to measure the concentrations of interleukin-1$\beta$ (IL-1$\beta$, PI301, Beyotime, Shanghai, China), interleukin-6 (IL-6, PI326, Beyotime, Shanghai, China), and tumor necrosis factor-$\alpha$ (TNF-$\alpha$, PT512, Beyotime, Shanghai, China) in primary microglia. LDH activity in primary hippocampal neurons was measured using a commercially available kit (C0018M, Beyotime, Shanghai, China).

Primary microglial cells were isolated using a discontinuous Percoll density gradient centrifugation method as described previously [14]. Briefly, the skull was carefully removed to extract brain tissue, which was then mechanically dissociated. To this homogenate was added 10 mL of sterile 1$\times$ DPBS containing 0.2% glucose. The resulting suspension was filtered through a 70 µm nylon cell strainer (CLS431752, Corning, NY, USA) and transferred to a 50 mL centrifuge tube (CLS352099, Corning, NY, USA). Cell suspensions were centrifuged through Percoll gradients, and the cell populations harvested from the interface between the 70% and 50% Percoll layers. The isolated cells were examined after immunofluorescence staining. Primary microglial cells and the mouse hippocampal neuronal cell line HT-22 were cultured in DMEM/F12 medium supplemented with 1% Penicillin/Streptomycin solution and 10% fetal bovine serum. Both cell lines were validated by STR profiling and tested negative for mycoplasma.

The CCK8 assay was utilized to evaluate cell viability. Primary hippocampal neurons were seeded into a 96-well plate. After an appropriate attachment period, 10 µL of CCK-8 solution (C0037, Beyotime, Shanghai, China) was added to each well, followed by incubation for 4 h at 37 °C in a humidified 5% CO₂ atmosphere. The absorbance at 450 nm was subsequently measured using a microplate reader (ELx800, BioTek, Santa Clara, CA, USA).

After routine dewaxing, antigen retrieval, and inactivation, the tissue sections were prepared at a thickness of 5 µm. The sections were incubated in a solution containing 0.2% Triton X-100 at room temperature for 20 minutes, followed by three 5-minute washes with phosphate-buffered saline with Tween-20 (PBST). Next, the samples were completely covered with a 5% bovine serum albumin (BSA) solution and incubated at room temperature for 30–60 minutes to block non-specific binding sites. After adding the appropriate primary antibody (ionized calcium-binding adapter molecule 1, Iba1, 1:100, ab283319, Abcam, Cambridge, UK), the sections were incubated overnight at 4 °C, then rinsed several times with PBS and incubated with horseradish peroxidase (HRP)-conjugated anti-mouse IgG secondary antibodies. Subsequently, an appropriate volume of tyramide signal amplification (TSA) dye was added and the sections incubated at room temperature in the dark for 10 minutes. Unbound antibodies were eluted using antibody elution buffer, followed by re-blocking with 5% BSA. An optimal concentration of primary antibodies (inducible nitric oxide synthase, iNOS, 1:100, ab210823, Abcam, Cambridge, UK; HCAR2, 1:100, AHR-012, Alomone labs, Jerusalem, Israel) was then added and incubated overnight at 4 °C. The sections were subsequently incubated with HRP-conjugated anti-rabbit IgG secondary antibodies and the TSA dye reapplied, ensuring the fluorescent color differed from that used in the initial staining. Finally, the sections were mounted using an anti-fade mounting medium, examined under a fluorescence microscope, and the images recorded.

TRIzol reagent (15596018CN, Sigma-Aldrich, St. Louis, MO, USA) was used to isolate total RNA, which was then reverse transcribed into cDNA using the PrimeScript RT reagent kit (RR037A, Takara, Kusatsu, Japan). Real-time PCR was performed on a 7300 Plus Real-Time PCR System (JM1966-018481, Thermo Fisher, Waltham, MA, USA) with SYBR Premix Ex Taq I (RR037A, Takara, Kusatsu, Japan). Each reaction mixture comprised 1 µL of cDNA template, 10 µL of PCR master mix, 5 pmol of each primer, and nuclease-free water to a final volume of 20 µL. The thermocycling conditions consisted of an initial denaturation at 95 °C for 13 s, followed by 40 cycles of 94 °C for 10 s, and 60 °C for 20 s. Relative mRNA expression levels were normalized to Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA as the internal control. Data analysis was conducted using the comparative threshold cycle ($\mathrm{\Delta }$$\mathrm{\Delta }$Ct) method. Primer sequences are listed in Table 1.

Cells were lysed with radioimmunoprecipitation assay (RIPA) buffer containing phenylmethylsulfonyl fluoride (PMSF). The extracted proteins were separated by 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and subsequently transferred to polyvinylidene fluoride (PVDF) membranes via electroblotting. The membranes were blocked for 1 h at room temperature and then incubated overnight at 4 °C with primary antibodies against phosphorylated protein kinase B (p-AKT, #4060, Cell Signaling Technology, Danvers, MA, USA), total protein kinase B (total-AKT, #4691, Cell Signaling Technology, Danvers, MA, USA), phosphorylated inhibitor of nuclear factor-kappa-B kinase subunits alpha and beta (p-IKK$\alpha$$\beta$, #2697, Cell Signaling Technology, Danvers, MA, USA), total inhibitor of NF$\kappa$B kinase subunits alpha and beta (total-IKK$\alpha$$\beta$, #8943, Cell Signaling Technology, Danvers, MA, USA), phosphorylated nuclear factor kappa-light-chain-enhancer of activated B cells (p-NF$\kappa$B, #3033, Cell Signaling Technology, Danvers, MA, USA), and total nuclear factor kappa-light-chain-enhancer of activated B cells (total-NF$\kappa$B, #6956, Cell Signaling Technology, Danvers, MA, USA). After washing, the membranes were incubated with HRP-conjugated secondary antibodies for 1 h at room temperature. The proteins were detected using an enhanced chemiluminescence (ECL) imaging kit (C10637, Thermo Fisher, Waltham, MA, USA), and visualized with a chemiluminescence imaging system (17001402, Bio-Rad, Hercules, CA, USA).

RNA sequencing was carried out through a commercially available service (BGI, the raw sequence data see the availability of data and materials). Briefly, total RNA was fragmented into short fragments and the mRNA enriched using oligo (dT) magnetic beads, followed by cDNA synthesis. Double stranded cDNA was purified and enriched by PCR amplification, after which the library products were sequenced using BGIseq-500. Gene Ontology (GO, http://geneontology.org/docs/download-ontology/) bioinformatics and Kyoto Encyclopedia of Genes and Genomes (KEGG, https://www.kegg.jp/kegg/pathway.html) pathway analyses were performed using the Dr. TOM approach, which is an in-house customized data mining system of the BGI. Altered expression of genes was expressed as log₂FC, representing log-transformed fold-change (log₂FC = log₂[B/A]), where A and B represent the values for gene expression under different treatment conditions.

All data are presented as the mean $\pm$ SEM and were analyzed using one-way Analysis of Variance (ANOVA) followed by Tukey’s post hoc test. Statistical analyses were performed using SPSS 22.0 software (IBM Corp., Chicago, IL, USA). A p-value of less than 0.05 was considered statistically significant.

To assess whether HCAR2 activation can mitigate corticosterone-induced depressive behaviors, we conducted the following tests across all experimental groups: tail suspension test (TST; Fig. 2A), forced swimming test (FST; Fig. 2B), sucrose preference test (SPT; Fig. 2C), and open field test (OFT; Fig. 2D). In the WT group, MK-6892 treatment significantly reduced corticosterone-induced depressive behaviors (TST: p 0.001; FST: p 0.001; SPT: p 0.001; OFT: p = 0.005). Furthermore, HCAR2 KO mice that received corticosterone treatment displayed markedly more severe depressive behaviors compared to WT mice subjected to the identical regimen. (TST: p = 0.015; FST: p 0.001; SPT: p = 0.016; OFT: p = 0.018). In the KO group, no statistically significant difference was observed between the Cor+MK-6892 group and the Cor-only group. These data indicate that HCAR2 activation can significantly alleviate corticosterone-induced depressive behaviors in mice.

Fig. 2.

Effects of HCAR2 activation on corticosterone-induced depressive behaviors. (A) Immobility time in the tail suspension test. (B) Immobility time in the forced swimming test. (C) Sucrose preference test. (D) Frequency of rearing behavior in the open field test. ***p 0.001, **p 0.01, *p 0.05; ns, not significant; WT, wild type; KO, knock out; Con, control; Cor, corticosterone.

The protective effects of HCAR2 activation in this murine model of depression were investigated by hematoxylin-eosin staining (Fig. 3A) and Nissl staining (Fig. 3C) across all experimental groups. In the WT group, HCAR2 activation in the depression model significantly enhanced the survival of hippocampal neurons, as evidenced by the reduced number of cells exhibiting nuclear pyknosis (p 0.001, Fig. 3B), and decreased the number of injured neurons (p 0.001, Fig. 3D). Moreover, HCAR2 KO mice exhibited more severe neurological impairments following corticosterone administration compared to their WT counterparts under identical treatment conditions (p = 0.005, Fig. 3B; p 0.001, Fig. 3D). We next evaluated the serum levels of 5-HT and NA. Activation of HCAR2 significantly reduced the corticosterone-induced depletion of monoamine neurotransmitters in WT mice (5-HT: p = 0.002; NA: p = 0.011, Fig. 3E). The HCAR2 KO depression model displayed a more pronounced depletion of monoamine neurotransmitters compared to the WT depression model (5-HT: p = 0.003; NA: p 0.001, Fig. 3E). The protective effect of MK-6892 was found to be specifically mediated via HCAR2, as no significant difference was observed between the depressive model group and the drug-treated group in KO mice. These data suggest that activation of HCAR2 can markedly reduce corticosterone-induced neuronal injury.

Fig. 3.

Effects of HCAR2 activation on corticosterone-induced hippocampal neuronal injury. (A) Representative hematoxylin-eosin stained images of the hippocampus from each experimental group. Scale bar = 20 µm. (B) Bar graph depicting the number of cells exhibiting nuclear pyknosis. (C) Representative Nissl-stained images of the hippocampus from each experimental group. Scale bar = 20 µm. (D) Bar graph showing the number of injured neurons. (E) Serum levels of monoamine neurotransmitter, as measured by ELISA. ***p 0.001, **p 0.01, *p 0.05; ns, not significant; WT, wild type; KO, knock out; Con, control; Cor, corticosterone; 5-HT, 5-Hydroxytryptamine; NA, norepinephrine.

To confirm the expression of HCAR2 in microglial cells, immunofluorescence staining was conducted on the hippocampus (Fig. 4A) and on primary microglial cells (Fig. 4B). HCAR2 was found to co-localize with Iba1, a marker for microglia, indicating that HCAR2 is expressed in microglial cells.

Fig. 4.

Co-localization of Iba1 and HCAR2 in vivo and in vitro. (A) Co-localization of Iba1 and HCAR2 in brain sections. Scale bar = 50 µm. The white arrow indicates the co-localization of Iba1 and HCAR2 within the hippocampal region. (B) Co-localization of Iba1 and HCAR2 in primary microglial cells. Scale bar = 10 µm. Iba1, ionized calcium-binding adapter molecule 1; LM, light microscopy.

We subsequently examined whether activation of HCAR2 in microglial cells could induce neuroprotective effects on cells from the hippocampal neuron HT-22 cell line in a co-culture model (Fig. 5A). Primary microglial cells were isolated from the specified experimental groups, and a 0.4 µm pore-sized membrane was used to segregate primary microglial cells from HT-22 cells. After co-culture for 48 h, the cell viability and LDH activity were assessed in each experimental group. HT-22 cells co-cultured with microglia isolated from WT mice and treated with a combination of Cor and MK-6892 were found to exhibit significantly greater cell viability (p = 0.005, Fig. 5B) and markedly lower LDH activity (p 0.001, Fig. 5C) compared to HT-22 cells co-cultured with microglia from WT mice treated with Cor alone. Furthermore, HT-22 cells co-cultured with microglia derived from KO mice treated with corticosterone exhibited significantly reduced cell viability and elevated LDH activity compared to HT-22 cells co-cultured with microglia from WT mice under identical treatment conditions. No significant differences were observed between the Cor and Cor+MK-6892 groups within the KO group. These data indicate that activation of HCAR2 in microglia may confer protection against corticosterone-induced neuronal injury in vitro.

Fig. 5.

HCAR2 activation alleviates hippocampal neuronal injury in a co-culture system. (A) Schematic diagram of the co-culture model. This figure was created using Adobe Illustrator software. (B) Cell viability in each experimental group. (C) LDH levels in each experimental group. ***p 0.001, **p 0.01, *p 0.05; ns, not significant; WT, wild type; KO, knock out; Con, control; Cor, corticosterone; LDH, lactate dehydrogenase.

The degree of M1 polarization in microglia was assessed by performing immunofluorescent staining for Iba1/iNOS in the hippocampus (Fig. 6A), as well as real-time qPCR analysis to evaluate the expression levels of iNOS and TNF-$\alpha$ in primary microglia (Fig. 6C). Immunofluorescent staining in WT mice demonstrated a markedly reduced proportion of Iba1/iNOS double-positive microglia in the Cor+MK-6892 group relative to the Cor-only group (p = 0.004, Fig. 6B). Consistent with these observations, real-time qPCR analysis in WT mice revealed the Cor+MK-6892 group exhibited markedly reduced levels of microglial M1 phenotype mRNA relative to the Cor-only group (iNOS: p 0.001; TNF-$\alpha$: p 0.001; Fig. 6C). Furthermore, Cor-treated KO mice displayed a significantly higher degree of M1 polarization relative to Cor-treated WT mice, as indicated by immunofluorescent staining (p = 0.02, Fig. 6B) and real-time qPCR analysis (iNOS: p 0.001; TNF-$\alpha$: p 0.001; Fig. 6C). In KO mice, no statistically significant difference was observed between the Cor+MK-6892 group and the Cor-only group. These data suggest that HCAR2 is effective at inhibiting microglial M1 polarization.

Fig. 6.

Activation of HCAR2 inhibits microglial M1 polarization. (A) Representative immunofluorescent staining for Iba1 and iNOS in the hippocampus. Scale bar = 100 µm. The white arrow indicates the co-localization of iNOS and Iba1 within the hippocampal region. (B) Quantification of the number of Iba1/iNOS double-positive microglia. (C) Relative mRNA levels of selected M1 phenotype markers in primary microglia. ***p 0.001, **p 0.01, *p 0.05; ns, not significant; WT, wild type; KO, knock out; Con, control; Cor, corticosterone.

Modulation of the protein kinase B-inhibitor of nuclear factor kappa-B kinase subunits alpha and beta-nuclear factor kappa-light-chain-enhancer of activated B cells (AKT-IKK$\alpha$$\beta$-NF$\kappa$B) pathway plays a critical role in mitigating inflammatory responses. Consequently, we performed Western blot analysis to examine the role of this pathway on the anti-inflammatory effects induced by HCAR2 (Fig. 7A,E). Corticosterone treatment resulted in significant upregulation of the expression of p-AKT (p 0.001, Fig. 7B), p-IKK$\alpha$$\beta$ (p 0.001, Fig. 7C), and p-NF$\kappa$B proteins (p 0.001, Fig. 7D), whereas MK-6892 treatment downregulated the expression of these proteins (p-AKT: p = 0.002, Fig. 7B; p-IKK$\alpha$$\beta$: p 0.001, Fig. 7C; p-NF$\kappa$B: p = 0.025, Fig. 7D) in primary microglia isolated from WT mice. However, no significant difference in protein expression was observed between the Cor+MK-6892 group and the Cor-only group in KO mice (Fig. 7F–H). In addition, the ELISA method was used to quantify the concentrations of selected pro-inflammatory cytokines. Treatment with MK-6892 significantly reduced the release of corticosterone-induced proinflammatory cytokines in microglia from WT mice (IL-1$\beta$: p = 0.02; IL-6: p = 0.018; TNF-$\alpha$: p = 0.005; Fig. 7I–K). Of note, no significant differences were observed between the Cor+MK-6892 group and the Cor-only group in KO mice. These data suggest that activation of HCAR2 can markedly attenuate the inflammatory response.

Fig. 7.

HCAR2 activation inhibits corticosterone-induced activation of the AKT-IKK$\alpha$$\beta$-NF$\kappa$B pathway in primary microglial cells. (A) Immunoblot analysis of p-AKT, p-IKK$\alpha$$\beta$, and p-NF$\kappa$B protein expression in primary microglial cells isolated from WT mice. (B–D) Quantitative bar graphs representing relative protein levels of p-AKT, p-IKK$\alpha$$\beta$, and p-NF$\kappa$B in primary microglial cells from WT mice. (E) Immunoblot analysis of p-AKT, p-IKK$\alpha$$\beta$, and p-NF$\kappa$B protein expression in primary microglial cells isolated from KO mice. (F–H) Quantitative bar graphs representing relative protein levels of p-AKT, p-IKK$\alpha$$\beta$, and p-NF$\kappa$B in primary microglial cells from KO mice. (I–K) Quantification of pro-inflammatory cytokine levels using ELISA. ***p 0.001, **p 0.01, *p 0.05; ns, not significant; WT, wild type; KO, knock out; Con, control; Cor, corticosterone; p-AKT, phosphorylated protein kinase B; p-IKK$\alpha$$\beta$, phosphorylated inhibitor of nuclear factor-kappa-B kinase subunits alpha and beta; p-NF$\kappa$B, phosphorylated nuclear factor kappa-light-chain-enhancer of activated B cells; total-AKT, total protein kinase B; total-IKK$\alpha$$\beta$, total inhibitor of NF$\kappa$B kinase subunits alpha and beta; total-NF$\kappa$B, total nuclear factor kappa-light-chain-enhancer of activated B cells; IL, interleukin; TNF-$\alpha$, tumor necrosis factor-alpha.

Comprehensive profiling of HCAR2-mediated transcriptional regulation in the brain was performed by extracting total RNA from microglia isolated from both Cor-treated and Cor+MK-6892-treated WT mice. This was followed by high-throughput sequencing and bioinformatic analysis. Heat map analysis of differential gene expression identified 174 differentially expressed genes (DEGs) between the Cor and Cor+MK-6892 groups, comprising 64 upregulated genes and 110 downregulated genes (Fig. 8A). KEGG analysis (Fig. 8B) revealed that HCAR2 activation in microglia primarily regulated genes associated with metabolic pathways (tryptophan metabolism, purine metabolism, etc.) and cellular processes (cell adhesion molecule, neutrophil extracellular trap formation, etc.). Gene Ontology enrichment analysis (Fig. 8C) revealed that microglia from the Cor+MK-6892 group and the Cor group display notable differences in functional annotations, signaling pathways, and specific biological processes. These data indicate that activation of HCAR2 results in transcriptomic alterations in microglia isolated from corticosterone-treated mice.

Fig. 8.

HCAR2 activation induces transcriptional changes in microglial cells. (A) Heatmap plot depicting differentially expressed genes between the depression model and the MK-6892-treated depression model. (B) KEGG enrichment analysis. (C) GO enrichment analysis. KEGG, Kyoto Encyclopedia of Genes and Genomes; GO, Gene Ontology bioinformatics.

We next investigated whether the anti-depressive and neuroprotective effects of HCAR2 activation are mediated by microglia. Mice were fed continuously with the CSF1R inhibitor PLX5622 for the entire experimental period to deplete microglia in vivo. AIN-76A chow was used as the vehicle control. Hematoxylin-Eosin staining (Fig. 9A) and Nissl staining (Fig. 9C) revealed that microglia depletion abrogated the neuroprotective effects of MK-6892 in Cor-induced neuronal injury (p 0.001, Fig. 9B; p 0.001, Fig. 9D). Results from ELISA showed that microglia depletion in the Cor+MK-6892 group led to a significant reduction in the levels of 5-HT and norepinephrine (NA) (5-HT: p = 0.037; NA: p = 0.013; Fig. 9E). Moreover, the Cor+PLX+MK-6892 group exhibited significantly more depressive behaviors compared to the Cor+MK-6892 group (TST: p = 0.029; FST: p = 0.002; SPT: p 0.001; OFT: p = 0.018; Fig. 9F). These data indicate the antidepressant and neuroprotective effects of HCAR2 activation are, at least in part, mediated by microglia.

Fig. 9.

The antidepressant and neuroprotective effects of HCAR2 are directly mediated through its action on microglia. (A) Representative hematoxylin-eosin stained images of the hippocampus from each experimental group. Scale bar = 20 µm. (B) Bar graph showing the number of cells with nuclear pyknosis. (C) Representative Nissl-stained images of the hippocampus from each experimental group. Scale bar = 20 µm. (D) Bar graph depicting the number of injured neurons. (E) Serum levels of monoamine neurotransmitters, as measured by ELISA. (F) Depressive-like behavior observed in each experimental group. ***p 0.001, **p 0.01, *p 0.05. Cor, corticosterone; Veh, Vehicle; PLX, PLX5622.